Genscript Biotech Corp
HKEX:1548

Watchlist Manager
Genscript Biotech Corp Logo
Genscript Biotech Corp
HKEX:1548
Watchlist
Price: 10.92 HKD
Market Cap: 23.2B HKD
Have any thoughts about
Genscript Biotech Corp?
Write Note

Genscript Biotech Corp
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genscript Biotech Corp
Income from Continuing Operations Peer Comparison

Comparables:
603259
300759
2269
300347
W
2268

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Genscript Biotech Corp
HKEX:1548
Income from Continuing Operations
-$325m
CAGR 3-Years
-5%
CAGR 5-Years
-61%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Income from Continuing Operations
ÂĄ8.6B
CAGR 3-Years
30%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Income from Continuing Operations
ÂĄ1.9B
CAGR 3-Years
15%
CAGR 5-Years
38%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Income from Continuing Operations
ÂĄ3B
CAGR 3-Years
2%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Income from Continuing Operations
ÂĄ1.3B
CAGR 3-Years
-20%
CAGR 5-Years
15%
CAGR 10-Years
29%
W
WuXi XDC Cayman Inc
HKEX:2268
Income from Continuing Operations
ÂĄ283.5m
CAGR 3-Years
121%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Genscript Biotech Corp's Income from Continuing Operations?
Income from Continuing Operations
-325m USD

Based on the financial report for Jun 30, 2024, Genscript Biotech Corp's Income from Continuing Operations amounts to -325m USD.

What is Genscript Biotech Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-61%

Over the last year, the Income from Continuing Operations growth was 27%. The average annual Income from Continuing Operations growth rates for Genscript Biotech Corp have been -5% over the past three years , -61% over the past five years .

Back to Top